Back to search results

Collection and Storage of Tissue and Blood Samples for Cancer Research

This study is collecting and storing tissue and blood samples from patients with cancer. These samples will be used in laboratories to create new models of cancer and test new cancer drugs. The goal is to better understand cancer and develop new treatments. You may be able to join if you are over 2 months old and have a confirmed cancer diagnosis, or if your doctor requests and receives approval for your participation. The study aims to collect these samples for up to 5 years.

Study design
This is an observational study involving up to 5000 participants. It is designed to procure biological tissues and materials for cancer research.
What's involved
Tissue and blood samples will be collected during procedures that are already part of your clinical care. These samples will then be stored for future analysis.
Compensation
Not stated in the trial record.
Follow-up
The procurement of tissue and blood specimens for research purposes will be measured for up to 5 years.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT02474160

Collection and Storage of Tissue and Blood Samples From Patients With Cancer

Recruiting
Not specifiedAges 2+Observational
National Cancer Institute LAO
~5,000 participants
Updated 2026-03-05 on ClinicalTrials.gov
What's tested:Cytology Specimen Collection Procedure

At a glance

Recruiting sites
22 of 140 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Procurement of tissue and blood specimens for research purposes
Measured over Up to 5 years

Conditions

Hematopoietic and Lymphatic System Neoplasm
Malignant Solid Neoplasm
Metastatic Malignant Solid Neoplasm
Recurrent Malignant Solid Neoplasm

Explore related trials

Hematologic NeoplasmSolid Neoplasm

NCT02474160

Where you'd take part

This study runs at 140 sites. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Ascension Via Christi Hospitals Wichita

    Wichita, Kansasstudy coordinator listed

    Recruiting

  • Augusta University Medical Center

    Augusta, Georgiastudy coordinator listed

    Recruiting

  • Baptist Memorial Hospital and Cancer Center-Memphis

    Memphis, Tennesseestudy coordinator listed

    Recruiting

  • Baptist Memorial Hospital and Cancer Center-Oxford

    Oxford, Mississippistudy coordinator listed

    Recruiting

  • Cancer Care Specialists of Illinois - Decatur

    Decatur, Illinoisstudy coordinator listed

    Recruiting

  • Cancer Center of Kansas - Wichita

    Wichita, Kansasstudy coordinator listed

    Recruiting

  • Corewell Health Grand Rapids Hospitals - Butterworth Hospital

    Grand Rapids, Michiganstudy coordinator listed

    Recruiting

  • CoxHealth South Hospital

    Springfield, Missouristudy coordinator listed

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • James H Doroshow · PRINCIPAL_INVESTIGATOR · National Cancer Institute (NCI)

Who to contact

Site Public Contact
800-378-9373
Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Patients older than 2 months of age who are being evaluated, treated, or enrolled in a clinical trial for cancer at participating sites
Patients with a histologically or cytologically confirmed diagnosis of cancer
Patients without histologically or cytologically confirmed diagnosis of cancer, but for whom approval has been requested and received from the coordinating site study coordinator
Requests for coordinating site approval should only be made if the patient's existing work-up at the time of the request demonstrates a combination of two or more of the following indicating the greater likelihood of a cancerous process in the assessment of the treating physician:
Radiographic imaging (computed tomography \[CT\], magnetic resonance imaging \[MRI\], etc.)
Elevated tumor markers
Clinical symptoms
Documented risk factors, known genetic changes (mutation, deletion, fusion, etc.), and/or known familial cancer history or syndrome
Complete blood count (CBC) w/differential indicative of a probable hematologic malignancy
If the patient will be undergoing surgical resection at a later time and will be accessible to approach for study participation at that time, resected material following cancer diagnosis confirmation is preferred
Important: Additional medical, genetic and/or demographic work-up should not be obtained solely for determination of eligibility for protocol 9846 by these criteria. Once available, final histology must be confirmed to the coordinating site detailing the cancer diagnosis for patients enrolled based on the above criteria
Patients with a newly diagnosed primary and/or metastatic solid tumor or hematologic malignancy for which they have not yet received treatment
Patients with a solid tumor or hematologic malignancy that is recurrent, newly metastasized, or progressing while on treatment indicated by:
Radiographic evidence of tumor growth, re-growth, and/or new metastases, OR
Documentation by the treating physician of clinical disease progression, OR
CBC w/differential and/or flow cytometry for hematologic malignancies
Patients currently undergoing treatment (adjuvant, neoadjuvant, etc.)
Specimen collection should occur as distant in time from the most recent drug administration as possible (e.g., after completion of a treatment cycle and immediately prior to initiation of the next cycle)
Specimens should not be collected from patients between doses within a single treatment cycle
Confirmation of viable residual malignancy and/or \< 90% tumor necrosis, fibrosis, or hemorrhage must be confirmed to the National Cancer Institute (NCI) coordinating site, as indicated in the final post-operative/post-procedure pathology and/or flow cytometry report
Patients with ongoing partial response (PR) or stable disease (SD) are eligible
Confirmation of viable malignancy and/or \< 90% tumor necrosis, fibrosis, or hemorrhage must be confirmed to the NCI coordinating site, as indicated in the final post-operative/post-procedure pathology and/or flow cytometry report
Ability to understand and willingness to sign a written informed consent document indicating their willingness to have their tissue or biologic fluid specimens used for research as outlined in this protocol
For pediatric patients, ability and willingness to assent to participation, using an explanation that is understandable/age appropriate, as well as receiving parental permission. Signature requirements for pediatric patients can be adjusted based on local guidelines

Exclusion

Patients with cancer-like syndromes and/or blood disorders such as systemic mastocytosis, Langerhans cell histiocytosis, chronic eosinophilic leukemia/hypereosinophilic syndrome, lymphomatoid granulomatosis, or monoclonal gammopathy of undetermined significance (MGUS)
Patients with invasive fungal infections
Patients with active and/or uncontrolled bacterial, fungal, or viral infections or who are still recovering from an infection
Actively febrile patients with uncertain etiology of febrile episode
All antibiotics prescribed for the treatment of a bacterial infection should be completed at least 1 week (7 days) prior to collection
Patients with a hematologic malignancy who are treated with an antibiotic, anti-fungal, and/or anti-viral medication for an active infection who then remain on the treatment for prophylaxis following resolution of the infection as assessed by the treating physician are not excluded
No recurrence of fever or other symptoms related to infection for at least 1 week (7 days) following completion of antibiotics
Patients receiving antibiotics, antifungals, and/or antivirals for prophylaxis are permissible
Antibiotics being administered topically at a location distant from the planned tissue collection site or eye drops for a localized infection are permissible
Patients with human immunodeficiency virus (HIV), active or chronic hepatitis (i.e., quantifiable hepatitis B virus \[HBV\]-deoxyribonucleic acid \[DNA\] and/or positive hepatitis B surface antigen \[HbsAg\], quantifiable hepatitis C virus \[HCV\]-ribonucleic acid \[RNA\]) or known history of HCV, HBV, or HIV; testing for HBV, HCV, HIV or other infections for eligibility will be performed only if clinically indicated
Patients with hepatitis A as indicated by anti-hepatitis A virus (HAV) IgM reactivity
Patients that are anti-HAV IgG reactive only are eligible
Specimen collections from patients with benign tumors including but not limited to desmoid tumors, carcinoma in situ, or ongoing evidence of complete disease response (CR)

What this trial measures

  • Procurement of tissue and blood specimens for research purposesUp to 5 years

    Tissues and venous blood will be stored, implanted immediately to generate patient-derived xenografts (which require fresh, viable cells), or placed immediately into in vitro cell culture to generate patient-derived cell lines (which require fresh, viable cells).